Cepheid’s Xpert Xpress CoV-2/Flu/RSV plus has gained a CE mark

Cepheid’s quick molecular diagnostic test for the qualitative detection of the viruses that cause COVID-19, Flu A, Flu B, and respiratory syncytial virus (RSV) infections from a single patient sample, Xpert Xpress CoV-2/Flu/RSV plus, has gained a CE mark.

The state-of-the-art plus version of the test meets the challenge of future viral mutations by providing a third gene target for SARS-CoV-2 detection. Xpert Xpress CoV-2/Flu/RSV plus can be used on any of Cepheid’s over thirty-five thousand GeneXpert Systems across the globe, and results are obtainable in about thirty-six minutes.

Chief Medical and Technology Officer, Cepheid, Dr. David Persing, stated: “This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with COVID-19 including Flu A, Flu B and respiratory syncytial virus. Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause COVID-19 and influenza will become increasingly important. The ability to collect one sample and run a single, highly-sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems.”